Document:

Blueprint

 

Exhibit 10.1

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN
CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR
DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933.

 

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THIS NOTE, THE
REPAYMENT OF ALL INDEBTEDNESS EVIDENCED HEREBY AND THE EXERCISE OF
ANY RIGHT OR REMEDY HEREUNDER BY THE HOLDER HEREOF ARE SUBJECT TO
THE TERMS AND CONDITIONS SET FORTH IN THAT CERTAIN SUBORDINATION
AGREEMENT, DATED ON OR ABOUT SEPTEMBER 30, 2017, BY AND BETWEEN
CROSSROADS FINANCIAL GROUP, LLC AND THE INITIAL HOLDER HEREOF. IN
THE EVENT OF ANY CONFLICT BETWEEN THE TERMS OF SUCH SUBORDINATION
AGREEMENT AND THIS NOTE, THE TERMS OF THE SUBORDINATION AGREEMENT
SHALL GOVERN AND CONTROL.

 

SECURED REVOLVING PROMISSORY NOTE

 

	
Up to
US$3,000,000.00   

	
October 4, 2019

 

For Value
Received, MusclePharm
Corporation, a Nevada corporation (“the Company”),
hereby unconditionally promises to pay to the order of Ryan Drexler (“Lender”), in
lawful money of the United States of America and in immediately
available funds, the principal sum of three million dollars
(US$3,000,000.00), or, if less, the aggregate unpaid principal
amount of all Advances (as defined below) (the “Revolving
Loan”), together with accrued and unpaid Interest (as
defined below) thereon and any Costs of Collection (as defined
below), due and payable on the dates and in the manner set forth
below in this Secured Revolving Promissory Note (the
“Note”).

 

1. Advances.
The Lender may, in its sole discretion, make one or more advances
(each, an “Advance,” and
collectively, the “Advances”) to
the Company, and the Company may, to the extent that the Lender
permits in his sole discretion, borrow funds from the Lender
hereunder. While the decision to make any Advance is at all times
within the sole discretion of the Lender, whether the limitation
set forth in clause 1(c) below is satisfied or not, it is
understood and agreed by the Company that, as further limitations
on the making of Advances by the Lender:

 

(a) each
request for an Advance shall be made by the Company in writing,
delivered to the Lender at least three (3) business days prior to
the requested date of such Advance, and shall specify the date of
such Advance and the amount of such Advance,

 

(b) requests
may only be made if no Event of Default (as defined below) has
occurred and is continuing,

 

1

 

 

(c) each
request shall be in the amount of at least ten thousand dollars
(US$10,000) and shall be in thousand-dollar increments,
and

 

(d) the
aggregate principal amount of all Advances outstanding at any time,
taking into account any and all Advances and repayments made as of
any date, shall in no event exceed three million dollars
(US$3,000,000.00).

 

The
Lender shall, and is hereby authorized to, record on the schedule
attached hereto the date and amount of each Advance and the date
and amount of each principal payment hereunder, provided,
that,
the failure of the Lender to record any Advance shall have no
effect on the obligation of the Company to repay the Advance or to
pay any other amount hereunder.

 

2. Interest.
Simple interest shall accrue on the outstanding principal amount of
each Advance from the date of such Advance until payment of such
Advance at a rate of twelve percent (12%) per annum
(“Interest”),
compounding annually. Interest shall be calculated on the basis of
a 365-day year for the actual number of days elapsed.

 

3. Costs
of Collection. If an Event of Default (as defined below) has
occurred, the Company shall pay the reasonable costs and expenses
(including reasonable attorney’s fees) incurred by the Lender
in the enforcement of the Lender’s rights hereunder
(“Costs
of Collection”).

 

4. Repayment.

 

(a) All
Advances made and not otherwise repaid, if any, all accrued
Interest not otherwise paid, if any, and all accrued Costs of
Collection not otherwise paid, if any (the “Repayment
Amount”), or at the sole discretion of the Lender, any
portion of the Repayment Amount, shall be due and payable on the
earlier of (a) the Maturity Date, as defined below, and (b) three
(3) days following any demand of the Lender (each such date, a
“Repayment
Date”). Demand for payment hereunder shall be made by
notice in writing, delivered by overnight courier to the
undersigned at 4400 Vanowen Street, Burbank, CA 91505, or sent by
email to Bill.Bush@musclepharm.com or by fax to 800/490-7165 (with
such demand being deemed made and effective one (1) business day
after being sent via overnight courier, and effective on the same
day it was sent (or, if not sent on a business day, on the
following business day) if sent via email or fax), setting out
details of the amount outstanding and the appropriate method of
payment.

 

(b) The
Company shall be entitled to prepay any outstanding principal
amount of any Advances without premium or penalty following at
least one (1) day’s advance written notice to the Lender,
provided,
that,
any such prepayment shall be accompanied by a payment by the
Company of all accrued and unpaid Interest and Costs of Collection
on such prepaid principal.

 

(c) Unless
earlier due and payable as provided in Section 4(a), the Repayment
Amount shall be due and payable on the earliest of (i) March 31,
2020, (ii) immediately upon receipt by the Company of a Notice of
Acceleration (as defined below) from the Lender as provided by
Section 8(a), and (iii) immediately upon the occurrence of an Event
of Default of the type described in Section 7(b) or (c), as
provided by Section 8(b) (the earliest such date being the
“Maturity
Date”).

 

 

2

 

 

(d) All
payments by the Company under this Note (including prepayments)
shall be made without set-off or counterclaim and be free and clear
and without any deduction or withholding for any taxes or fees of
any nature whatever, unless the obligation to make such deduction
or withholding is imposed by law. All payments hereunder shall be
made in cash in immediately available U.S. Dollars.

 

5. Application
of Payments. Payments made hereunder shall be applied,
first, to accrued but unpaid Costs of Collection, if any; second,
to accrued but unpaid Interest, if any; third to unpaid principal
on the Revolving Loan, if any (beginning with the earliest Advance
for which principal remains unpaid and continuing in chronological
order to subsequent Advances). Any excess amounts remaining after
such application shall be returned to the Company within three (3)
business days.

 

6. Secured
Note. This Note is the Note referred to in, and is executed
and delivered in connection with, that certain Security Agreement
dated as of even date herewith between the Company and the Lender
(as the same may from time to time be amended, modified or
supplemented or restated, the “Security
Agreement”). This Note and all obligations of the
Company hereunder, including without limitation all Advances, all
Interest, and any Costs of Collection, are secured by the
Collateral, as such term is defined in the Security Agreement. No
reference in this Note to the Security Agreement shall impair the
obligation of the Company, which is absolute and unconditional, to
pay all amounts under this Note strictly in accordance with the
terms of this Note.

 

7. Default.
There shall exist an event of default hereunder (an
“Event of
Default”) if

 

(a) the
Company fails to repay or pay any and all unpaid principal, accrued
and unpaid Interest, accrued and unpaid Costs of Collection and all
other amounts owing under this Note and the Security Agreement when
due and payable pursuant to the terms of this Note unless such
failure is cured within three (3) days of the date the Lender has
given notice of such breach to the Company;

 

(b) the
Company or any of its subsidiaries files any petition or action for
relief under any bankruptcy, reorganization, insolvency or
moratorium law or any other law for the relief of, or relating to,
debtors, now or hereafter in effect, or makes any general
assignment for the benefit of creditors;

 

(c) an
involuntary petition is filed against the Company or any of its
subsidiaries (unless such petition is dismissed or discharged
within sixty (60) days) under any bankruptcy statute or similar law
now or hereafter in effect, or a custodian, receiver, trustee,
assignee for the benefit of creditors (or other similar official)
is appointed to take possession, custody or control of any property
of the Company;

 

(d) the
Company breaches any other material term of this Note or the
Security Agreement (unless, in the case of any curable material
breach, such material breach is cured within thirty (30) days of
the earlier of the date on which (x) the Lender has given notice of
such breach to the Company and (y) the Company has actual knowledge
of such breach);

 

3

 

 

(e) the
Company amends or modifies the terms of any existing indebtedness
in a manner that increases the principal amount thereof or the
interest rate applicable thereto, accelerates the maturity of the
obligations thereunder or otherwise adversely affects the Lender;
provided,
that, the foregoing shall not constitute an Event of Default
if undertaken, caused, approved, consented to or voted in favor of
by the Lender in his capacity as an employee, officer or director
of the Company;

 

(f) a
final judgment or judgments for the payment of money aggregating in
excess of $1,000,000 that are not covered by insurance or an
indemnity from a creditworthy party are rendered against the
Company and/or any of its subsidiaries and which judgments are not,
within thirty (30) days after the entry thereof, bonded, discharged
or stayed pending appeal, or are not discharged within thirty (30)
days after the expiration of such stay;

 

(g) the
Company fails to pay, when due, giving effect to any applicable
grace period, any payment with respect to any funded indebtedness
in excess of $500,000 due to any third party (other than, with
respect to unsecured funded indebtedness only, payments contested
by the Company in good faith by proper proceedings and with respect
to which adequate reserves have been set aside for the payment
thereof in accordance with U.S. generally accepted accounting
principles) or is otherwise in breach or violation of any agreement
for monies owed or owing in an amount in excess of $500,000, other
than (i) unsecured trade obligations in the ordinary course of
business, which breach or violation permits the other party thereto
to declare a default or otherwise accelerate amounts due thereunder
or (ii) matters disclosed in the Company’s securities
filings; provided, that, the
foregoing shall not constitute an Event of Default if undertaken,
caused, approved, consented to or voted in favor of by the Lender
in his capacity as an employee, officer or director of the Company;
or

 

(h) there
exists any circumstances or events that would, with or without the
passage of time or the giving of notice, result in a default or
event of default under any agreement binding the Company or any
subsidiary, which default or event of default would or is likely to
have a material adverse effect on the business, assets, operations
or financial condition of the Company and its subsidiaries, taken
as a whole; provided, that, the
foregoing shall not constitute an Event of Default if such
circumstances or events are undertaken, caused, approved, consented
to or voted in favor of by the Lender in his capacity as an
employee, officer or director of the Company.

 

8. Acceleration
and Remedies.

 

(a) Upon
the occurrence and during the continuance of any Event of Default
described in clause (a) or clauses (d) through (h) of Section 7 of
this Note, the Lender shall be entitled to accelerate the entire
indebtedness hereunder, including all principal, all Interest and
all Costs of Collection, which shall become due and payable
following receipt by the Company of written notice of the
occurrence of said Event of Default (“Notice of
Acceleration”).

 

(b) Upon
the occurrence and during the continuance of any Event of Default
described in clauses (b) or (c) of Section 7 of this Note, the
entire indebtedness hereunder, including all principal, all
Interest, and all Costs of Collection, shall be automatically
accelerated, and shall be immediately due and payable, without any
demand, notice, or other action of the Lender or any other person
or entity.

 

4

 

 

(c) Notwithstanding
anything to the contrary in this Note or any other agreement,
instrument or document, upon the occurrence and during the
continuance of any Event of Default, the Lender may exercise any
and all rights and remedies it may have under this Note, the
Security Agreement, or applicable law.

 

9. Covenants.

 

(a) Restrictions
on Additional Indebtedness and Liens and Subordination. The
Company may not incur or suffer to exist any Indebtedness (as
defined below) other than Permitted Indebtedness (as defined below)
or any Lien (as defined below) other than Permitted Liens (as
defined below).

 

(i) “Indebtedness”
shall mean any and all indebtedness for borrowed money; all
obligations in respect of any deferred purchase price; all
obligations in respect of capital leases; all reimbursement
obligations in respect of letters of credit, surety bonds and
similar instruments; all obligations evidenced by notes, bonds,
loan agreements, debentures and similar instruments; and all
guarantee obligations and contingent obligations in respect of any
of the foregoing.

 

(ii) “Permitted
Indebtedness” shall mean (a) Indebtedness evidenced by
this Note; (b) Indebtedness in respect of taxes, fees, assessments
or other governmental charges or levies, either not delinquent or
being contested in good faith by appropriate proceedings;
provided,
that, the Company maintains adequate reserves therefor; (c)
Indebtedness existing as of the date hereof and set forth on the
schedule of Permitted Indebtedness attached hereto, or pursuant to
an instrument set forth on such schedule or disclosed in the
Company’s securities filings; (d) Indebtedness to trade
creditors (including suppliers) incurred in the ordinary course of
business, including Indebtedness incurred in the ordinary course of
business with corporate credit cards; (e) extensions, refinancings,
repayment and renewals of the obligations under this Note and under
any Permitted Indebtedness described in clauses (c) or (d) above,
provided,
that, the principal amount is not increased or the terms
modified to impose materially more burdensome terms upon the
Company unless such increase or modification is undertaken, caused,
approved, consented to or voted in favor of by the Lender in his
capacity as an employee, officer or director of the Company; (f)
Subordinated Indebtedness incurred after the date of this Note and
approved by a majority of the independent directors of the Board;
and (g) Indebtedness evidenced by that certain Amended and Restated
Convertible Secured Promissory Note dated November 8, 2017 issued
by the Company to the Lender.

 

(iii) “Subordinated
Indebtedness” means secured and/or unsecured
Indebtedness expressly subordinated to the obligations of the
Company to the Lender hereunder and under the Security Agreement,
including in payment and lien priority, pursuant to a subordination
agreement in form and substance acceptable to the Lender in its
sole discretion.

 

(iv) “Lien”
shall mean any lien, claim, encumbrance or similar interest in or
on any asset, including without limitation any security interest or
mortgage.

 

5

 

 

(v) “Permitted
Lien” shall mean (a) Liens securing Indebtedness
evidenced by this Note; (b) Liens for taxes, fees, assessments or
other governmental charges or levies, either not delinquent or
being contested in good faith by appropriate proceedings,
provided,
that, the Company maintains adequate reserves therefor; (c)
claims of materialmen, mechanics, carriers, warehousemen,
processors or landlords arising out of operation of law so long as
the obligations secured thereby (i) are not past due or (ii) are
being properly contested and for which the Company has established
adequate reserves; (d) Liens consisting of deposits or pledges made
in the ordinary course of business in connection with
workers’ compensation, unemployment insurance, social
security and similar laws; (e) Liens on equipment (including
capital leases) to secure purchase money Indebtedness existing as
of the date hereof, or any permitted refinancing thereof, so long
as such security interests do not apply to any property of the
Company other than the equipment so acquired, and the Indebtedness
secured thereby does not exceed the cost of such equipment, and
provided,
that, any extension, renewal or replacement Lien shall be
limited to the property encumbered by the existing Lien and the
principal amount of the Indebtedness being extended, renewed, or
refinanced (as may have been reduced by any payment thereon) does
not increase; (f) Liens on accounts, inventory, machinery,
equipment, instruments, documents, chattel paper, general
intangibles and other assets to secure purchase money Indebtedness
under agreements set forth on the schedule of Permitted
Indebtedness attached hereto; (g) Liens to secure the obligations
under agreements set forth on the schedule of Permitted Liens
attached hereto or to secure Permitted Indebtedness; and (h) Liens
securing Indebtedness evidenced by that certain Amended and
Restated Convertible Secured Promissory Note dated November 8, 2017
issued by the Company to the Lender.

 

10. Waivers.
The Company, for itself and its legal representatives, successors
and assigns, hereby expressly waives demand, protest, presentment,
notice of dishonor, notice of acceptance, and notice of protest,
and all other demands and notices in connection with the delivery,
acceptance, performance, default or enforcement of this
Note.

 

11. Transfer;
Successors and Assigns. The terms and conditions of this
Note shall inure to the benefit of and be binding upon the
respective successors and assigns of the Company and the Lender.
Notwithstanding the foregoing, the Lender may not assign, pledge or
otherwise transfer this Note without the prior written consent of
the Company. Subject to the preceding sentence, this Note may be
transferred only upon surrender of the original Note for
registration of transfer, duly endorsed, or accompanied by a duly
executed written instrument of transfer in form satisfactory to the
Company. Thereupon, a new note for the same principal amount and
interest will be issued to, and registered in the name of, the
transferee. Interest and principal are payable only to the
registered holder of this Note.

 

12. Governing
Law. This Note shall be governed by and construed in
accordance with the laws of the State of New York (without giving
effect to any conflict of laws principles that would require
application of the laws of another jurisdiction other than Section
5-1401 of the General Obligations Law of the State of New
York.).

 

6

 

 

13. Jurisdiction.
Each of the Company and the Lender irrevocably submits to the
jurisdiction of the courts of the State of New York and of the
United States sitting in the State of New York, and of the courts
of its own corporate or individual domicile with respect to actions
or proceedings brought against it as a defendant, for purposes of
all proceedings. Each of the Company and the Lender irrevocably
waives, to the fullest extent permitted by law, any objection which
it may now or hereafter have to the laying of venue of any
proceeding and any claim that any proceeding has been brought in an
inconvenient forum. Any process or summons for purposes of any
proceeding may be served on the Company or the Lender, as
applicable, by mailing a copy thereof by registered mail, or a form
of mail substantially equivalent thereto, addressed to it at its
address as provided for notices under this Note.

 

14. Waiver
of Jury Trial. Each of the
Company and the Lender hereby irrevocably waives any and all right
to trial by jury in any proceeding.

 

15. Notices.
Any notice required or permitted by this Note shall be in writing
and shall be deemed sufficient when delivered personally or by
overnight courier or sent by email or fax (upon customary
confirmation of receipt), or forty-eight (48) hours after being
deposited in the U.S. mail as certified or registered mail with
postage prepaid, addressed to the party to be notified at such
party’s address or fax number as set forth on the signature
page, as subsequently modified by written notice, or if no address
is specified on the signature page, at the most recent address set
forth in the Company’s books and records; provided, that, any
notice to the Company by the Lender also shall be provided to the
independent directors of the Board.

 

16. Amendments and Waivers. Any term of this
Note may be amended only with the written consent of the Company
and the Lender. Any amendment or waiver effected in accordance
herewith shall be binding upon the Company, the Lender and each
transferee of this Note.

 

17. Entire
Agreement. This Note, together with the Security Agreement,
constitutes the entire agreement between the Company and the Lender
pertaining to the subject matter hereof, and any and all other
written or oral agreements existing between the Company and the
Lender are expressly canceled.

 

18. Counterparts.
This Note may be executed in any number of counterparts, each of
which will be deemed to be an original and all of which together
will constitute a single agreement.

 

19. Loss
of Note. Upon receipt by the Company of evidence
satisfactory to it of the loss, theft, destruction or mutilation of
this Note or any Note exchanged for it, and indemnity satisfactory
to the Company (in case of loss, theft or destruction) or surrender
and cancellation of such Note (in the case of mutilation), the
Company will make and deliver in lieu of such Note a new Note of
like tenor.

 

7

 

 

20. Interest
Rate Limitation. Notwithstanding anything to the contrary
contained herein, the interest paid or agreed to be paid under this
Note shall not exceed the maximum rate of non-usurious interest
permitted by applicable law (the “Maximum
Rate”). If the Lender shall receive interest in an
amount that exceeds the Maximum Rate, the excess interest shall be
applied to the principal amount remaining owed under this Note or,
if it exceeds such unpaid principal amount, refunded to the
Company. In determining whether the interest contracted for,
charged, or received by the Lender exceeds the Maximum Rate, the
Lender may, to the extent permitted by applicable law, (i)
characterize any payment that is not principal as an expense, fee,
or premium rather than interest, (ii) exclude voluntary prepayments
and the effects thereof, and (iii) amortize, prorate, allocate and
spread in equal or unequal parts the total amount of interest
throughout the contemplated term of this Note.

 

21. Indemnification.
The Company shall, to the fullest extent permitted by law,
indemnify (but only to the extent of and out of Company assets) the
Lender against all reasonable expenses (including reasonable
attorneys’ fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred by the Lender in
connection with any claim, action, suit or proceeding, whether
civil, criminal, administrative or investigative, before or by any
court or any administrative or legislative body or authority, in
which the Lender is involved, as a party or otherwise, or with
which the Lender may be threatened, arising in connection with this
Note or the Security Agreement (each, an “Action”), except to the extent the
same has been finally adjudicated to constitute fraud, gross
negligence or willful misconduct of the Lender or a breach by the
Lender of this Note or the Security Agreement. Promptly after
receipt by the Lender of notice of the commencement or threatened
commencement against it of any third party Action, the Lender will
notify the Company. The Company will be entitled to assume the
defense of the Action unless the Lender shall have reasonably
concluded that a conflict may exist between the Company and the
Lender in conducting the defense of the Action. If the Company
assumes the defense of any Action in accordance with the provisions
of this Section, it will not be liable to the Lender for any legal
or other expenses subsequently separately incurred by the Lender in
connection with the defense of such Action. The Company shall not
be liable for any settlement of a third-party Action effected
without its written consent, which consent may not be unreasonably
withheld.

 

22. Severability.
In the event that any provision of this Note is invalid or
unenforceable under any applicable statute or rule of law, then
such provision shall be deemed inoperative to the extent that it
may conflict therewith and shall be deemed modified to conform with
such statute or rule of law. Any such provision which may prove
invalid or unenforceable under any law shall not affect the
validity or enforceability of any other provision of this
Note.

 

[Remainder
of Page Intentionally Left Blank]

 

8

 

 

IN WITNESS WHEREOF, the undersigned have
duly executed this Secured Revolving Promissory Note as of the date
indicated herein.

 

 

	

 

	MusclePharm
Corporation	

 

	

 

	

 

	

 

	

 

	

	
By:  

	
/s/ Brian
Casutto  

	

 

	

 

	

 

	
Name: 
Brian
Casutto

	

 

	

 

	

 

	

Title: 
EVP,
Sales & Marketin

	

 

 

Acknowledged
and Agreed:

 

Ryan Drexler

 

/s/ Ryan Drexler

 

 

9

 

 

Schedule of Permitted Indebtedness

 

Purchase
and Sale Agreement, dated as of January 11, 2016, between the
Company and Prestige Capital Corporation, as amended or modified
through the date hereof, and as hereafter amended or modified with
the consent of the Lender in his capacity as such or as a director
or officer of the Company, providing for aggregate borrowings up to
a maximum principal amount of $12,000,000 (as
amended).

 

Loan
and Security Agreement, dated as of October 6, 2017, among the
Company, Canada MusclePharm Enterprises Corp. and Crossroads
Financial Group, LLC, as amended or modified through the date
hereof, and as hereafter amended or modified with the consent of
the Lender in his capacity as such or as a director or officer of
the Company, providing for aggregate borrowings up to a maximum
principal amount of $4,000,000 (as amended).

 

Capital
leases outstanding at June 30, 2017 described in Note 9 to the
Condensed Consolidated Financial Statements contained in the
Company’s 10-Q for the quarter ended June 30,
2017.

 

 

Schedule of Permitted Liens

 

Loan
and Security Agreement, dated as of October 6, 2017, among the
Company, Canada MusclePharm Enterprises Corp. and Crossroads
Financial Group, LLC, as amended or modified through the date
hereof, and as hereafter amended or modified with the consent of
the Lender in his capacity as such or as a director or officer of
the Company, providing for aggregate borrowings up to a maximum
principal amount of $4,000,000 (as amended).

 

 

 

 

10

 

 

SCHEDULE OF LOAN AND PAYMENTS OF PRINCIPAL

 

TO SECURED REVOLVING PROMISSORY NOTE

 

OF
MUSCLEPHARM CORPORATION

 

DATED
__________, 2019

 

	

Principal

Amount
of

Advance

	

 

Date

	

Principal

Amount

Paid

	

 

Unpaid

Balance

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
 

 

 

 

11Blueprint

 

Exhibit 10.2

 

Security Agreement

 

This
Security Agreement (this
“Agreement”),
dated as of October 4, 2019, is entered into between Ryan Drexler, an individual
(“Grantee”), and
MusclePharm Corporation, a
Nevada corporation, as grantor (“Grantor”).

 

Background

 

WHEREAS,
Grantor and Grantee have entered into a Secured Revolving
Promissory Note dated as of even date herewith (as amended, restated, or otherwise
modified from time to time, the “Note”); and

 

WHEREAS,
in consideration of, and as a condition precedent to, the
advancement of funds to Grantor under the Note, the Grantor wishes
to grant the security interests contemplated by this Agreement to
the Grantee as security for the Grantor’s obligations under
the Note.

 

Agreement

 

NOW,
THEREFORE, in consideration of the promises contained herein and
for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Grantor hereby
agrees, for the benefit of Grantee, as follows:

 

ARTICLE I 

 

Certain
Definitions

 

Section
1.01. Definitions.

 

The
terms “Account,”
“Equipment,”
“Inventory,” and
“Proceeds” shall
have the meanings ascribed to such terms in the UCC.

 

As used
herein:

 

“Collateral” shall have the meaning
set forth in Section 2.01.

 

“Dispute” means any pending,
decided or settled opposition, injunction, action, claim,
counterclaim, lawsuit, proceeding, hearing, investigation,
complaint, arbitration, mediation, demand, decree or formal
enquiry, or any other dispute, disagreement, or claim of any
kind.

 

“Excluded Property” means (i) any
permit, license, contract or lease to the extent that (and in each
case only for so long as) such grant of a security interest therein
or assignment thereof is prohibited by any applicable laws or is
prohibited by, or constitutes a breach or default under or results
in the termination of or gives rise to a right on the part of the
parties thereto other than Grantor to terminate, such permit,
license, contract or lease, except to the extent that such laws or
the term in such permit, license, contract or lease providing for
such prohibition, breach, default or right of termination are
ineffective or rendered unenforceable under applicable laws
(including the UCC), and (ii) any property owned by Grantor on the
date hereof or hereafter acquired that is subject to a lien
permitted to be incurred pursuant to clause (e) of the definition
of Permitted Lien contained in the Note.

 

 

 

 

1

 

 

 

 

“Governmental Authority” means the
government of the United States or any other country, any state or
other political subdivision thereof, any supranational or
multinational authority, and any entity, body or authority
exercising executive, legislative, judicial, regulatory or
administrative functions of, or pertaining to, any of the
foregoing.

 

“Intellectual Property” means (a)
any and all copyright rights, copyright applications, copyright
registrations and like protections in each work or authorship and
derivative work thereof, whether published or unpublished and
whether or not the same also constitutes a trade secret, now or
hereafter existing, created, acquired or held (collectively, the
“Copyrights”);
(b) any and all trade secrets, and any and all intellectual
property rights in computer software and computer software products
now or hereafter existing, created, acquired or held; (c) any and
all design rights that may be available, now or hereafter existing,
created, acquired or held; (d) all patents, patent applications and
like protections including, without limitation, improvements,
divisions, continuations, renewals, reissues, extensions and
continuations-in-part of the same (collectively, the
“Patents”); (e)
any trademark and servicemark rights, whether registered or not,
applications to register and registrations of the same and like
protections, and the entire goodwill connected with and symbolized
by such trademarks, other than any intent-to-use United States
trademark applications for which an amendment to allege use or
statement of use has not been filed under 15 U.S.C.
§ 1051I or 15 U.S.C. § 1051(d), respectively,
or if filed, has not been deemed in conformance with 15 U.S.C.
§ 1051(a) or examined and accepted, respectively, by the
United States Patent and Trademark Office, provided that, upon such filing
and acceptance, such intent-to-use applications shall be included
in the definition of Collateral (collectively, the
“Trademarks”);
(f) all mask work registrations or applications therefor or similar
rights, now owned or hereafter acquired (collectively, the
“Mask Works”);
(g) any and all claims for damages by way of past, present and
future infringements of any of the rights included above, with the
right, but not the obligation, to sue for and collect such damages
for said use or infringement of the intellectual property rights
identified above; (h) all licenses or other rights to use any of
the Copyrights, Patents, Trademarks, or Mask Works and all license
fees and royalties arising from such use to the extent permitted by
such license or rights; (i) all amendments, extensions, renewals
and extensions of any of the Copyrights, Trademarks, Patents, or
Mask Works; and (j) all proceeds and products of the foregoing,
including without limitation all payments under insurance or any
indemnity or warranty payable in respect of any of the
foregoing.

 

 “Secured
Obligations” means all obligations of Grantor under or
in respect of the Note and this Agreement.

 

“UCC” means the Uniform Commercial
Code as in effect on the date hereof in the State of New York, as
amended from time to time, and any successor statute; provided that
if by reason of mandatory provision of law, the perfection or the
effect of perfection or non-perfection of the security interest in
the Collateral is governed by the Uniform Commercial Code of
another jurisdiction, “UCC” means the Uniform
Commercial Code as in effect in such other jurisdiction for
purposes of the provision hereof relating to such perfection or
effect of perfection or non-perfection.

 

 

 

 

2

 

 

 

 

Section
1.02. Note Definitions. Unless otherwise
defined herein or the context otherwise requires, terms used in
this Agreement, including its preamble and recitals, have the
meanings provided in the Note.

 

Section
1.03. UCC Definitions. Unless otherwise
defined herein or the context otherwise requires, terms for which
meanings are provided in the UCC are used in this Agreement,
including its preamble and recitals, with such meanings; provided,
however, that the term “instrument” shall be such term
as defined in Article 9 of the UCC rather than Article 3 of the
UCC.

 

Section
1.04. Interpretation; Headings. Each term used
in any exhibit to this Agreement and defined in this Agreement but
not defined therein shall have the meaning set forth in this
Agreement. Unless the context otherwise requires,
(i) “including” means “including, without
limitation” and (ii) words in the singular include the
plural and words in the plural include the singular. A reference to
any party to this Agreement, the Note, or any other agreement or
document shall include such party’s successors and permitted
assigns. A reference to any agreement or order shall include any
amendment of such agreement or order from time to time in
accordance with the terms hereof and thereof. A reference to any
legislation, to any provision of any legislation or to any
regulation issued thereunder shall include any amendment thereto,
any modification or re-enactment thereof, any legislative provision
or regulation substituted therefor and all regulations and
statutory instruments issued thereunder or pursuant thereto. The
headings contained in this Agreement are for convenience and
reference only and do not form a part of this Agreement. Section,
article and exhibit references in this Agreement refer to sections
or articles of, or exhibits to, this Agreement unless otherwise
specified.

 

ARTICLE II

 

Security
Interest

 

Section
2.01. Grant
of Security Interest.

 

(a) As collateral
security for the Secured Obligations, Grantor hereby grants to
Grantee a continuing Lien on and a continuing first priority
(subject to any Permitted Liens (as such term is defined in the
Note)) security interest in and lien and mortgage on all of
Grantor’s and Grantor’s subsidiaries’ right,
title, and interest in each and all of its assets and properties,
wherever the same may be now or hereafter located, whether now
owned by or owing to, or hereafter existing or hereafter acquired
by or arising in favor of, Grantor or its subsidiaries (including
under any trade name or derivations thereof), whether tangible or
intangible, and all products and Proceeds thereof (together, the
“Collateral”),
including all of the following and all products and Proceeds
thereof:

 

(i) all Intellectual
Property (the “Intellectual
Property Collateral”);

 

(ii) all
goods and Equipment, including all laboratory equipment, computer
equipment, office equipment, machinery, fixtures, vehicles
(including motor vehicles and trailers), and any interest in any of
the foregoing, and all attachments, accessories, accessions,
replacements, substitutions, additions, and improvements to any of
the foregoing, wherever located;

 

(iii) all
Inventory, including all merchandise, raw materials, parts,
supplies, packing and shipping materials, work in process and
finished products including such inventory as is temporarily out of
Grantor’s custody or possession or in transit and including
any returns upon any accounts or other proceeds, including
insurance proceeds, resulting from the sale or disposition of any
of the foregoing and any documents of title representing any of the
above, and Grantor’s books relating to any of the
foregoing;

 

 

 

 

3

 

 

 

 

(iv) all
Accounts (including healthcare receivables), all contract rights or
rights to payment of money, leases, license agreements, franchise
agreements, commercial tort claims, documents, instruments
(including any promissory notes), chattel paper (whether tangible
or electronic), cash and cash equivalents, insurance policy claims
and proceeds, all general intangibles (including payment
intangibles), all letters of credit, certificates of deposit,
letters of credit rights (whether or not the letter of credit is
evidenced by a writing), securities, material intercompany notes,
and all other investment property, supporting obligations, and
financial assets, in each case, unless otherwise defined in this
Agreement, as defined in the UCC;

 

(v) all books, records,
databases, customer lists, credit files, computer files, programs,
printouts and other computer materials and records, and all other
information relating to the foregoing and any general intangibles
at any time evidencing or relating to any of the foregoing;
and

 

(vi) any
and all claims, rights and interests in any of the above and all
substitutions for, additions, attachments, accessories, accessions
and improvements to and replacements, products, proceeds and
insurance proceeds of any or all of the foregoing.

 

(b) With respect to the
Intellectual Property Collateral, Grantor hereby grants to Grantee
all of Grantor's and Grantor’s subsidiaries’ right,
title and interest in, to and under the Intellectual Property
Collateral, including, without limitation, the
following:

 

(i) Any and all claims
for damages by way of past, present and future infringements of any
of the rights in the Intellectual Property Collateral, with the
right, but not the obligation, to sue for and collect such damages
for said use or infringement of the rights in the Intellectual
Property Collateral;

 

(ii) All
licenses or other rights to use any of the Intellectual Property
Collateral and all license fees and royalties arising from such use
to the extent permitted by such license or rights;

 

(iii) All
amendments, extensions, renewals and extensions of any of the
Intellectual Property Collateral; and

 

(iv) All
proceeds and products of the Intellectual Property Collateral,
including without limitation all payments under insurance or any
indemnity or warranty payable in respect of any of the
foregoing.

 

Notwithstanding
the foregoing, in no event shall the Collateral include any
Excluded Property; provided that, notwithstanding the foregoing, a
security interest shall be, and is hereby, granted in (A) any
property immediately upon such property ceasing to be Excluded
Property and (B) any and all proceeds, products, substitutions and
replacements of Excluded Property to the extent such proceeds,
products, substitutions and replacements do not themselves
constitute Excluded Property.

 

(c) Grantor shall, and
shall cause its subsidiaries to, take such commercially reasonable
steps as Grantee reasonably requests in writing to obtain the
consent of, or waiver by, any person whose consent or waiver is
necessary, by contract or law, for the grant of the security
interest in the Collateral or any portion thereof, including any
license or other contract, whether now existing or entered into in
the future.

 

 

 

 

4

 

 

 

 

Section
2.02. Continuing
Security Interest.

 

(a) This Agreement
creates a continuing security interest in the Collateral and shall:
(i) remain in full force and effect until the date on which the
Secured Obligations are paid and performed in full; (ii) be binding
upon Grantor and its successors, transferees and assigns; and (iii)
inure, together with the rights and remedies of Grantee, to the
benefit of Grantee and its successors and assigns.

 

(b) Grantee shall have
all rights to perfect, continue, maintain, and protect
Grantee’s interest and rights under the Note.

 

(c) Upon the date on
which the Secured Obligations are paid and performed in full, the
security interest granted herein shall automatically terminate and
all rights to the Collateral, in each case to the extent the
Collateral has not been previously disposed of or dealt with in
accordance with this Agreement or otherwise, shall revert to
Grantor. Upon any such termination, and from time to time following
such termination, Grantee will, at Grantor’s sole expense,
promptly execute and deliver to Grantor such instruments and
documents necessary and as Grantor shall reasonably request to
evidence such termination.

 

Section
..03. Grantor Remains Liable. Anything herein
to the contrary notwithstanding: (a) Grantor shall remain liable
under the contracts included in the Collateral to the extent set
forth therein and as to all other Collateral; (b) the exercise by
Grantee of any of its rights and remedies hereunder shall not
operate to release Grantor from any of its duties or obligations
under any contracts included in the Collateral and as to any other
Collateral; and (c) Grantee shall not have any obligation or
liability under any such contracts included in the Collateral or as
to any other Collateral by reason of this Agreement, and Grantee
shall not be obligated to perform or fulfill any of the obligations
or duties of Grantor thereunder or to take any action to collect or
to (i) make any inquiry as to the nature or sufficiency of any
payment Grantor may be entitled to receive thereunder,
(ii) present or file and claim or (iii) enforce any claim
for payment assigned hereunder.

 

Section
2.04. Authorization
to File Financing Statements.

 

(a) Grantor hereby
irrevocably appoints Grantee its attorney-in-fact and authorizes
Grantee at any time and from time to time, without notice to
Grantor, to file in any UCC jurisdiction or other appropriate
location any financing statements or other appropriate documents
and any amendments thereto and continuations thereof that: (i)
describe or indicate the Collateral (x) as all assets of
Grantor or words of similar effect, regardless of whether any
particular asset comprised in the Collateral falls within the scope
of Article 9 of the UCC or such jurisdiction, or (y) with
greater detail; and (ii) contain any other information required by
Article 9 of the UCC or other applicable law or as otherwise
appropriate for the sufficiency or filing office acceptance of any
financing statement or other document or amendment or continuation,
including, as applicable, whether Grantor is an organization, the
type of organization and any organization identification number
issued to Grantor.

 

(b) Grantor agrees to
furnish any such information required for purposes of
Section 2.04(a) to Grantee promptly upon request.

 

 

 

 

5

 

 

 

 

Section
2.05. Recordation. Grantor authorizes the
Commissioner for Patents, the Commissioner for Trademarks and the
Register of Copyrights and any other government officials to record
and register this Agreement upon request by Grantee.

 

Section
2.06. Other Actions. Without limiting any
other obligations of Grantor in respect of the Collateral set forth
herein or in the Note, Grantor hereby agrees to take any action
reasonably requested by Grantee to effect the attachment,
perfection and first priority of (subject to any Permitted Liens
(as such term is defined in the Note)), and the ability of Grantee
to enforce, Grantee’s security interest in any and all of the
Collateral (and to pay all reasonable documented out-of-pocket
expenses incurred in connection therewith), including any of the
following: (a) comply with any provision of any law as to any
Collateral if compliance with such provision is a condition to
attachment, perfection or priority of, or ability of Grantee to
enforce, Grantee’s security interest in any material portion
of the Collateral; (b) obtain Governmental Authority and all other
third party consents and approvals, including without limitation
any consent of any licensor, lessor or other person obligated on
the Collateral, to the extent such consent or approval is a
condition to attachment, perfection or priority of, or ability of
Grantee to enforce, Grantee’s security interest in any
material portion of the Collateral; (c) furnish to Grantee, from
time to time, statements and schedules further identifying and
describing the Collateral and such other reports in connection with
the Collateral as Grantee may reasonably request, and all in
reasonable detail; and (d) at Grantee’s request, appear in
and defend any Dispute that may affect Grantor’s title to or
Grantee’s security interest in any material portion of the
Collateral.

 

ARTICLE III

 

Representations
and Warranties

 

Grantor
represents and warrants to Grantee as follows:

 

Section
3.01. Grantor’s Legal Status. (a) Except
as set forth in Schedule 3.01, Grantor’s exact legal name is
that indicated in the preamble hereto, Grantor has not, during the
past five years, been known by or used any other corporate or
fictitious name, nor been a party to any merger, acquisition or
consolidation; and (b) Grantor is an organization of the type and
organized in the jurisdiction set forth in the preamble
hereto.

 

Section
3.02. Ownership; No Liens. Grantor owns the
Collateral free and clear of any liens, security interests, or
other encumbrances, except for the security interest created by
this Agreement and any Permitted Liens. No effective security
agreement, financing statement, assignment, equivalent security,
lien or other instrument similar in effect covering all or any part
of the Collateral is on file or of record in any public office,
except such as may have been filed in favor of Grantee relating to
this Agreement or in connection with any Permitted
Liens.

 

Section
3.03. Validity.

 

(a) Except as set forth
on Schedule 3.03, Grantor has good title to, has
rights in, and has the power to transfer each item of the
Collateral, free and clear of any and all liens, security
interests, and other encumbrances except any Permitted Liens, and
has full power and authority to grant to Grantee the security
interest in such Collateral pursuant to this
Agreement.

 

 

 

 

6

 

 

 

 

(b) Subject to
Permitted Liens, this Agreement creates a valid security interest
in the Collateral securing the payment and performance in full of
the Secured Obligations. Upon filing appropriate financing
statements in the applicable filing offices, all filings,
registrations and recordings presently necessary to create and
perfect the first priority security (subject to Permitted Liens)
interest granted to Grantee in the Collateral for which a security
interest may be perfected by filing will have been
taken.

 

Section
3.04. Authorization; Approval. No
authorization or approval by, and no notice to or filing with, any
Governmental Authority or any person except for the consent of
holders of Permitted Liens: (a) is required for the grant by
Grantor of the security interest granted hereby (except as to any
later arising or acquired commercial tort claims) or for the
execution, delivery, and performance of this Agreement by Grantor;
or (b) is required for the perfection of the security interest of
Grantee in the Collateral or exercise by Grantee of its rights and
remedies hereunder, other than the filing of financing statements
in the appropriate offices, to the extent that the security
interest in the Collateral can be perfected by the filing of
financing statements.

 

Section
3.05. Enforceability. This Agreement is the
legal, valid and binding obligation of Grantor, enforceable against
Grantor in accordance with its terms, subject, as to enforcement of
remedies, to bankruptcy, insolvency, reorganization, moratorium or
other laws affecting creditors’ rights generally or general
equitable principles.

 

ARTICLE IV

 

Covenants

 

Section
4.01. Covenants.

 

(a) For so long as this
Agreement shall remain in effect, Grantor hereby covenants and
agrees to abide by and perform all obligations and covenants set
forth in the Note and herein, including, without limitation, the
conversion obligations (as applicable) and restrictions on
indebtedness and liens set forth in the Note.

 

(b) Grantor agrees that
it will not interfere with any right, power and remedy of Grantee
provided for in this Agreement or now or hereafter existing at law
or in equity or by statute or otherwise, or the exercise or
beginning of the exercise by Grantee of any one or more of such
rights, powers or remedies.

 

(c) Without limiting
any of the foregoing covenants, Grantor agrees (i) not to use
or permit any of the Collateral to be used unlawfully in any
material respect or in material violation of any provision of the
Note or any applicable law or any policy of insurance covering the
Collateral and (ii) to pay promptly when due all taxes now or
hereafter imposed upon or affecting any of the
Collateral.

 

 

 

 

7

 

 

 

 

ARTICLE V

 

Rights
and Duties of Grantee

 

Section
5.01. Grantee
Appointed Attorney-in-Fact.

 

(a) Grantor, on behalf
of itself and its subsidiaries, hereby irrevocably appoints Grantee
(and each of Grantee’s designees) as Grantor’s and such
subsidiaries’ true and lawful attorney-in-fact, with full
authority and power in the place and stead of Grantor and such
subsidiaries and in the name of Grantor, such subsidiaries, Grantee
or otherwise, from time to time in Grantee’s discretion from
and after the occurrence and during the continuation of an Event of
Default, to take any appropriate action and to execute any
instrument that Grantee may deem reasonably necessary or advisable
to accomplish the purposes of this Agreement, including: (i) to
ask, demand, collect, enforce, sue for, recover, compromise,
receive, and acquit and receipts for monies due and to become due
under or in respect of any of the Collateral; (ii) to receive,
endorse, and collect any checks, drafts or other instruments,
documents, and chattel paper in connection with clause (a)
above; (iii) to file any claims or take any action or institute any
proceedings (or to settle, adjust or compromise any such
proceeding) that Grantee may deem necessary or desirable for the
collection of any of the Collateral or otherwise to enforce the
rights of Grantee with respect to any of the Collateral; (iv) to
perform the affirmative obligations of Grantor hereunder; (v) to
execute and deliver, for and on behalf of Grantor and such
subsidiaries, any and all instruments, documents, agreements, and
other writings necessary or advisable for the exercise on behalf of
Grantor and its subsidiaries of any rights, benefits or options
created or existing under or pursuant to the Collateral (including
but not limited to executing and delivering to any Governmental
Authority any correspondence or other documentation necessary or
advisable to effect a transfer of any regulatory approval); and
(vi) to execute endorsements, assignments, or other instruments of
transfer with respect to the Collateral.

 

(b) Notwithstanding the
foregoing, Grantee shall not be obligated to and shall have no
liability to Grantor or any third party for failure to take any of
the actions described in Section 5.01(a).

 

(c) Grantor hereby
acknowledges, consents and agrees that the power of attorney
granted pursuant to this Section 5.01 is irrevocable and
coupled with an interest.

 

Section
5.02. Grantee May Perform. If, after and
during the continuance of an Event of Default, Grantor fails to
perform any agreement or covenant contained herein, Grantee may
itself (but shall not be obliged to) perform, or cause performance
of, such agreement or covenant, and in connection therewith Grantee
shall be entitled to act as Grantor’s true and lawful
attorney-in-fact and with the full benefits of Section 5.01
hereof.

 

 

 

 

8

 

 

 

 

ARTICLE VI

 

Remedies

 

Section
6.01. Certain Remedies. If any Event of
Default shall have occurred and is continuing: (a) Grantee may
exercise in respect of the Collateral, in addition to other rights
available to it at law or in equity or otherwise, or under the
Note, all the rights and remedies of a secured party on default
under the UCC or any other applicable law, and also may: (i)
require Grantor to, and Grantor hereby agrees that it shall, at
Grantor’s expense and promptly upon request of Grantee,
assemble all or part of the Collateral as directed by Grantee and
make it available to Grantee at a place to be designated by Grantee
that is reasonably convenient to both parties; (ii) exercise any
and all rights and remedies of Grantor under or in connection with
the Collateral; (iii) foreclose or otherwise enforce
Grantee’s security interest in any manner permitted by law or
provided for in this Agreement, and sell any of all of the
Collateral in any commercially reasonable manner; and (iv) without
notice or demand of legal process, all of which are hereby
expressly waived by Grantor, enter into property where any of the
Collateral is located and take possession thereof; provided,
however, that notwithstanding the foregoing, Grantee may transfer
the Collateral or any portion thereof without any preparation or
processing; and (b) Grantor, on behalf of itself and its
subsidiaries, specifically waives (to the extent permitted by law)
all rights of redemption, stay or appraisal which it has or may
have under any law now existing or hereafter adopted.

 

ARTICLE VII

 

Miscellaneous

 

Section
7.01. Assignments. Grantor and Grantee shall
not be permitted to assign this Agreement without the prior written
consent of the other party and any purported assignment in
violation of this Section 7.01 shall be null and void.

 

Section
7.02. Successors and Assigns. The provisions
of this Agreement shall be binding upon and inure to the benefit of
the parties hereto and their respective successors and permitted
assigns.

 

Section
7.03. Notices. All notices and other
communications shall be given as set forth in the
Note.

 

Section
7.04. Entire Agreement. This Agreement and the
Note contain the entire agreement between the parties hereto
relating to the subject matter hereof and supersede all oral
statements and prior writings with respect thereto.

 

Section
7.05. Modification. No provision hereof may be
amended or modified except by an agreement or agreements in writing
executed by Grantor and Grantee.

 

Section
7.06. No
Delay; Waivers; etc.

 

(a) No failure to
exercise and no delay in the exercise, on the part of Grantee, of
any right, remedy, power or privilege hereunder and no course of
dealing with respect thereto shall impair such right, remedy, power
or privilege or be construed to or operate as a waiver thereof, nor
shall any single or partial exercise of any power or right
hereunder preclude other or further exercise thereof or the
exercise of any other right, remedy, power or privilege. Grantee
shall not be deemed to have waived any rights hereunder unless such
waiver shall be in writing and signed by Grantee.

 

 

 

 

9

 

 

 

 

(b) Grantor waives any
right to require Grantee to proceed against any person or to
exhaust any of the Collateral or to pursue any remedy in such
Grantee’s power.

 

Section
7.07. Severability. If any provision of this
Agreement shall be held to be invalid, illegal or unenforceable,
then, to the fullest extent permitted by law, the validity,
legality and enforceability of the remaining provisions shall not
in any way be affected or impaired thereby.

 

Section
7.08. Governing Law. This Agreement and the
Note shall be governed by and construed in accordance with the laws
of the State of New York (without giving effect to any conflict of
laws principles that would require application of the laws of
another jurisdiction other than Section 5-1401 of the General
Obligations Law of the State of New York).

 

Section
7.09. Jurisdiction. Grantor irrevocably
submits to the jurisdiction of the courts of the State of New York
and of the United States sitting in the State of New York, and of
the courts of its own corporate domicile with respect to actions or
proceedings brought against it as a defendant, for purposes of all
proceedings. Grantor irrevocably waives, to the fullest extent
permitted by law, any objection which it may now or hereafter have
to the laying of venue of any proceeding and any claim that any
proceeding has been brought in an inconvenient forum. Any process
or summons for purposes of any proceeding may be served on Grantor
by mailing a copy thereof by registered mail, or a form of mail
substantially equivalent thereto, addressed to it at its address as
provided for notices under the Note.

 

Section
7.10. Waiver of Jury Trial. Grantor hereby irrevocably waives any and all
right to trial by jury in any proceeding.

 

Section
7.11. Waiver of Immunity. To the extent that
Grantor has or hereafter may be entitled to claim or may acquire,
for itself or any of its assets, any immunity from suit,
jurisdiction of any court or from any legal process (whether
through service or notice, attachment prior to judgment, attachment
in aid of execution, or otherwise) with respect to itself or any of
its property, Grantor hereby irrevocably waives such immunity in
respect of its obligations hereunder to the fullest extent
permitted by law.

 

Section
7.12. Counterparts; Facsimile Signatures. This
Agreement may be executed and delivered by facsimile signature
(including PDF) and in any number of counterparts, each of which
shall be deemed an original but all of which together shall
constitute one and the same instrument.

 

Section
7.13. Rights Not Exclusive. The rights, powers
and remedies of Grantee under this Agreement are cumulative and are
not exclusive of, and shall be in addition to, all rights, powers
and remedies given to Grantee by virtue of any law and/or the Note,
all of which rights, powers and remedies shall be cumulative and
may be exercised successively or concurrently without impairing
Grantee’s security interest in the Collateral.

 

 

 

 

10

 

 

 

 

Section
7.14. Indemnification. Grantor shall, to the
fullest extent permitted by law, indemnify (but only to the extent
of and out of Grantor assets) Grantee against all reasonable
expenses (including reasonable attorneys’ fees), judgments,
fines and amounts paid in settlement actually and reasonably
incurred by Grantee in connection with any claim, action, suit or
proceeding, whether civil, criminal, administrative or
investigative, before or by any court or any administrative or
legislative body or authority, in which Grantee is involved, as a
party or otherwise, or with which Grantee may be threatened,
arising in connection with the Note or this Agreement (each, an
“Action”),
except to the extent the same has been finally adjudicated to
constitute fraud, gross negligence or willful misconduct of Grantee
or a breach by Grantee of the Note or this Agreement. Promptly
after receipt by Grantee of notice of the commencement or
threatened commencement against it of any third party Action,
Grantee will notify Grantor. Grantor will be entitled to assume the
defense of the Action unless Grantee shall have reasonably
concluded that a conflict may exist between Grantor and Grantee in
conducting the defense of the Action. If Grantor assumes the
defense of any Action in accordance with the provisions of this
Section, it will not be liable to Grantee for any legal or other
expenses subsequently separately incurred by Grantee in connection
with the defense of such Action. Grantor shall not be liable for
any settlement of a third-party Action effected without its written
consent, which consent may not be unreasonably
withheld.

 

 [Remainder
of page intentionally blank]

 

 

 

11

 

 

IN
WITNESS WHEREOF, the undersigned have duly executed this Agreement
as of the date first set forth above.

 

 

Ryan Drexler, an individual

 

as Grantee

 

/s/ Ryan
Drexler________________________

 

 

MusclePharm Corporation, a Nevada corporation

 

as Grantor

 

By: 

/s/ Brian
Casutto_______________

 

Name:                       

Brian
Casutto

 

Title:                       

EVP, Sales &
Marketing

                  

  

[Signature
page to Security Agreement]

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]